Ryvu Therapeutics Announces Two Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting (SITC 2019)
Ryvu Therapeutics and Selvita Announce registration of Corporate Split by the National Court Register of Poland
Ryvu Announces Shareholder Approval of Corporate Split and New Name of Ryvu Therapeutics for Oncology Development Company
What we do
We challenge current treatment paradigms
At Ryvu, we develop therapeutics that address clinical limitations of current treatments in oncology.
Our pipeline includes candidates with differentiated properties from kinase, synthetic lethality, immuno-oncology and immunometabolism programs.
Ryvu Therapeutics (Selvita Oncology) was founded in 2007. Since 2014, the company has been listed on Warsaw Stock Exchange under the ticker SLV.
Ryvu Therapeutics is organized for highly efficient R&D driven by breakthrough science, aiming to realize full value potential for its shareholders, partners and employees.See More